M/I Homes Down Over 5%, On Track for Lowest Close Since July 2025 -- Data Talk
Dow Jones2026/10/21 17:47M/I Homes, Inc. (MHO) is currently at $117.62, down $6.45 or 5.2%
--Would be lowest close since July 21, 2025, when it closed at $114.28
--On pace for largest percent decrease since Oct. 22, 2025, when it fell 6.14%
--Currently down three of the past four days
--Down 12.96% month-to-date
--Down 8.08% year-to-date; on pace for worst year since 2022, when it fell 25.73%
--Down 32.76% from its all-time closing high of $174.92 on Oct. 16, 2024
--Down 10.69% from 52 weeks ago (Oct. 22, 2025), when it closed at $131.69
--Down 27.84% from its 52-week closing high of $163.00 on June 26, 2026
--Would be a new 52-week closing low
--Traded as low as $116.09; lowest intraday level since July 21, 2025, when it hit $113.85
--Down 6.43% at today's intraday low; largest intraday percent decrease since April 10, 2025, when it fell as much as 6.85%
All data as of 1:44:54 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 21, 2026 13:47 ET (17:47 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
